Research demonstrates that intracellular administration of GSDMB-specific antibodies can significantly and selectively hinder the metastasis, migration, and therapeutic resistance associated with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (109). This evidence concerns the gene GSDMB and breast cancer.